Navigation Links
Myriad Genetics Presents Azixa's Mode of Action at AACR

Azixa Shows Dual Activity as Vascular Disrupting Agent and Tubulin Inhibitor

SALT LAKE CITY, UT, April 17, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented studies that characterize the mode of action of its investigational new drug, Azixa™, as a vascular disrupting agent, at the annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, California.

Azixa has been previously shown to be an inducer of apoptosis, and a potent inhibitor of human tumor cell growth and survival in cell culture, regardless of the multiple drug resistance (MDR) stature of the tumors. Key to this activity is its ability to inhibit the formation of microtubules. Data on Azixa's activity against human cancers of the breast, ovary, prostate, colon and pancreas will be presented at ASCO, the American Society of Clinical Oncology, later this year. Recently, Myriad researchers have uncovered a second mode of action known as vascular disruption.

Vascular disrupting agents target a tumor's endothelium, the inner layer of cells lining a blood vessel, which leads to a loss of blood supply to the tumor and subsequent tumor cell death. In recent studies, Azixa induced cell death in several primary types of endothelium, including micro-vessel endothelial cells. Moreover, in human ovarian cancer xenografts, a single dose of Azixa induced dramatic tumor blood vessel damage and tumor cell death within 24 hours.

"We are excited by the potential of Azixa in several different types of cancer," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "Azixa's dual mode of action and its extraordinary ability to cross the blood-brain barrier may allow it to be a more effective chemotherapeutic than anything available to treat brain cancer today."

Azixa's dual mode of action i
'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Tumor Origin Technology at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Azixa Mode Action AACR
(Date:8/21/2014)... , Aug. 21, 2014  Zacks.com announces the list ... Zacks Equity Research analysts discuss the latest news and events ... the blog include the Hewlett-Packard (NYSE: HPQ - Free Report ... Bulkers, Inc. (NYSE: SB - Free Report ), GlaxoSmithKline ... International N.V. (NYSE: FI - Free Report ). ...
(Date:8/21/2014)... 21, 2014 InfinityQS International, Inc., the ... Intelligence , today announces Infusion Chicago, its 9 ... be held Oct. 9-10, 2014, at the Chicago ... showcase the necessity for implementing a quality system ... Intelligence to gain insight into production processes. Complimentary ...
(Date:8/21/2014)... , Aug. 21, 2014  The board of directors ... leading provider of clinical trial imaging solutions, today announced ... chief financial officer, effective immediately.  Mr. Groff has held ... 2013.  He joined VirtualScopics in January 2006 as an ... 2013. "When the board of VirtualScopics asked ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... FRANCISCO, June 22, 2011 Autonomy Corporation plc ... infrastructure software for the enterprise, today announced that the ... Autonomy,s flagship Web Content Management (WCM) platform, has twice ... Site Monitor performance report. The Swiss Pharma Site Monitor ...
... FALL RIVER, Mass., June 21, 2011 Millstone ... introduced an advanced version of its online inventory ... refinement, Millstone launched a new online, password-protected system ... place orders, and manage distribution.  Benefits of the ...
Cached Medicine Technology:Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 2Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 3Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 4Millstone Medical Outsourcing Introduces Advanced Version of Online Inventory Management System 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 According ... Type & Application - Global Trends & Forecast ... with an analysis and forecast of the market ... to $38,729 million by 2019, at a significant ... market data tables and 44 figures spread through ...
(Date:8/22/2014)... Hallandale Beach, Florida (PRWEB) August 22, 2014 ... treatment for Lasik in Fort Lauderdale at the most ... patients get better eyesight through their advanced Lasik treatments. ... available worldwide and the Braverman Eye Center has been ... thousands of patients live a glasses-free and contact lenses-free ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across the ... with Crohn,s disease (CD), reports Inflammatory Bowel Diseases ... Foundation of America (CCFA). The journal is published ... Wolters Kluwer Health . , The study ... of the genome in children with CD, according to Professor ...
(Date:8/22/2014)... confused with lactose intolerance. However, these are two entirely ... lactose intolerance do not digest lactose properly because they ... of the potentially much more dangerous cow milk allergy, ... its own IgE antibodies. , According to statistics, about ... from a genuine milk allergy. Less adults are diagnosed ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
Breaking Medicine News(10 mins):Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3
... are warned of side effect that could hamper immigration ... widely used cancer drug capecitabine can cause people to ... they,re trying to enter the United States, an oncologist ... medical oncology at the National Cancer Centre in Singapore, ...
... learned at the Canadian-run military hospital in Kandahar, Afghanistan ... a London, Ontario physician who has served two tours ... professor in the Department of Surgery at the Schulich ... Western Ontario and a general surgeon at the London ...
... Recondo Technology, a leading provider of revenue ... today announced the firm,s selection as one ... Recondo as one of the top 100 companies ... http://www.newscom.com/cgi-bin/prnh/20090527/LA23009LOGO ) , (Logo: ...
... Johnson recognized by business leaders for vision, determination and ... Search America , a part of ... health care, today announced that its president, Daniel Johnson, ... & Young Entrepreneur of the Year(R) Award in Minnesota ...
... to develop new and more effective therapies to fight ... Team" of scientists and clinicians that is co-led by ... Department of Energy,s Lawrence Berkeley National Laboratory. , The ... Entertainment Industry Foundation charitable organization aimed at moving cancer ...
... Care Reform; Mark McClellan ModeratesWASHINGTON, May 27 ... to presenting comprehensive legislation to overhaul the nation,s ... Secretary Michael Leavitt and former Senate Majority Leader ... highlight the need for transparency and inclusion in ...
Cached Medicine News:Health News:Fingerprints May Vanish With Cancer Drug 2Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2Health News:Recondo Technology Wins Red Herring 100 North America Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 2Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 3Health News:NPC Newsmaker Program Hosts Briefing on Health Care Reform with Former HHS Secretary Michael Leavitt and Former Senate Majority Leader Tom Daschle 2
... are designed for the retraction of ... lesions. Reduced obstruction when working within ... range of blade sizes from 2 ... change and release, malleable material allows ...
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...
Telescopic Diamond-Dissectors for delicate sharp tissue preparation. Total/working lengths 220/240 mm with protective sleeve....
Epstein Curettes 3.0 mm, length 8" (203 mm)....
Medicine Products: